PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Highlights the firm's ability to meet near-term obligations and cover interest expenses. For conservative value investors, strong liquidity and coverage metrics are critical to avoid distress or forced dilution.
3.68
Current Ratio 0.75–0.9x Biotechnology median of 4.56. John Neff would want to see better short-term coverage or stable cash flows.
3.68
Quick Ratio 0.75–0.9x Biotechnology median of 4.42. John Neff might push for better working capital control.
3.59
Cash Ratio above 1.5x Biotechnology median of 2.37. Joel Greenblatt might see a strategic advantage in crisis periods.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.